Application of interim PET-CT in first-line treatment decision-making for lymphoma

Abstract

Recent advances in lymphoma treatment have significantly improved the survival of patients; however, the current approaches also have varying side effects. To overcome these, it is critical to implement individualized treatment according to the patient’s condition. Therefore, the early identification of high-risk groups and targeted treatment are important strategies for prolonging the survival time and improving the quality of life of patients. Interim positron emission tomography-computed tomography (PET-CT) has a high prognostic value, which can reflect chemosensitivity and identify patients for whom treatment may fail under this regimen. To date, many prospective clinical studies on interim PET (iPET)-adapted therapy have been conducted. In this review, we focus on the treatment strategies entailed in these studies, as well as the means and timing of iPET assessment, with the aim of exploring the efficacy and existing issues regarding iPET-adapted treatment. It is expected that the improved use of PET-CT examination can facilitate treatment decision-making to identify precise treatment options.

摘要

随着淋巴瘤治疗手段的发展与改进,患者的生存得到了极大的改善。然而,目前的治疗方法存在不同程度的副作用,因此需尽可能减少治疗带来的不良反应,并根据患者的情况实施个体化治疗。基于此,尽早识别高危人群并进行针对性治疗是延长患者生存时间和提高生活质量的重要策略。中期正电子发射计算机断层扫描(PET-CT)具有较高的预后价值,可以反映化疗敏感性并识别在该方案下治疗可能失败的患者。迄今为止,已经进行了多项关于中期PET(iPET)引导治疗的前瞻性临床研究。本综述重点关注上述研究中涉及的治疗策略以及iPET评估的方法和时间,通过探索iPET指导治疗的效果和存在的问题,以期iPET在治疗引导中能发挥更大的价值。